Efficacy of Natalizumab therapy in patients of African descent with relapsing multiple sclerosis: Analysis of AFFIRM and SENTINEL data

Archives of Neurology

Volumn 68, Issue 4, 2011, Pages 464-468

  Cree, Bruce A C ^a   Stuart, William H ^b   Tornatore, Carlo S ^c   Jeffery, Douglas R ^d   Pace, Amy L ^e   Cha, Choon H ^e  

^a UCSF Multiple Sclerosis Center   (United States)

^b Multiple Sclerosis Center of Atlanta   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d WAKE FOREST BAPTIST HEALTH   (United States)

^e BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB; PLACEBO;

AFRICA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLURRED VISION; CAUCASIAN; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ETHNIC DIFFERENCE; EXTREMITY PAIN; FALLING; FATIGUE; HEADACHE; HUMAN; HYPESTHESIA; INSOMNIA; META ANALYSIS; MULTIPLE SCLEROSIS; MUSCLE SPASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 79953852809     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.45     Document Type: Article

References (10)

1. Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ. Multiple sclerosis: severity and progression rate in African Americans compared with whites. Am J Phys Med Rehabil. 2003;82(8):582-590. (Pubitemid 36890406)
2. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63(11):2039-2045. (Pubitemid 39636249)
3. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 2006;66(8):1235-1240.
4. Cree BA, Reich DE, Khan O, et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol. 2009;66(2):226-233.
5. Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005;62(11):1681-1683. (Pubitemid 41626662)
6. Caillier SJ, Briggs F, Cree BA, et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis [published correction appears in J Immunol. 2009;182:2551]. J Immunol. 2008;181(8):5473-5480.
7. Reich D, Patterson N, De Jager PL, et al. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet. 2005;37(10):1113-1118. (Pubitemid 41486665)
8. Miller DH, Soon D, Fernando KT, et al; AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68(17):1390-1401.
9. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
10. Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.